39945-51-2Relevant articles and documents
New azolyl-derivatives as multitargeting agents against breast cancer and fungal infections: synthesis, biological evaluation and docking study
Maccallini, Cristina,Gallorini, Marialucia,Sisto, Francesca,Akdemir, Atilla,Ammazzalorso, Alessandra,De Filippis, Barbara,Fantacuzzi, Marialuigia,Giampietro, Letizia,Carradori, Simone,Cataldi, Amelia,Amoroso, Rosa
, p. 1632 - 1645 (2021/07/28)
Nonsteroidal aromatase inhibitors (NSAIs) are well-established drugs for the therapy of breast cancer. However, they display some serious side effects, and their efficacy can be compromised by the development of chemoresistance. Previously, we have report
Potent inhibition of Norwalk virus by cyclic sulfamide derivatives
Dou, Dengfeng,Tiew, Kok-Chuan,He, Guijia,Mandadapu, Sivakoteswara Rao,Aravapalli, Sridhar,Alliston, Kevin R.,Kim, Yunjeong,Chang, Kyeong-Ok,Groutas, William C.
experimental part, p. 5975 - 5983 (2011/11/07)
A new class of compounds that exhibit anti-norovirus activity in a cell-based system and embody in their structure a cyclosulfamide scaffold has been identified. The structure of the initial hit (compound 2a, ED50 4 μM, TD50 50 μM) has been prospected by exploiting multiple points of diversity and generating appropriate structure-activity relationships.
Carbazole inhibitors of histamine receptors for the treatment of disease
-
, (2012/01/04)
The present invention relates to carbazole compounds, pharmaceutical compositions comprising them, and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
